Genfit SA
(NASDAQ : GNFT)

( )
GNFT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.59%154.960.0%$1509.75m
NVAXNovavax, Inc. 2.55%79.1878.2%$568.86m
AMGNAmgen, Inc. -1.11%222.541.4%$546.33m
GILDGilead Sciences, Inc. -2.18%67.341.0%$534.08m
BIIBBiogen, Inc. -1.22%219.601.8%$496.23m
BNTXBioNTech SE 2.69%160.700.0%$493.59m
REGNRegeneron Pharmaceuticals, Inc. 0.34%605.252.7%$434.03m
ILMNIllumina, Inc. -3.77%331.783.3%$370.86m
VRTXVertex Pharmaceuticals, Inc. -0.23%226.581.9%$358.72m
SNSSSunesis Pharmaceuticals, Inc. -4.71%2.630.7%$183.85m
EXASEXACT Sciences Corp. -0.42%68.8917.9%$173.71m
INCYIncyte Corp. -0.85%73.522.4%$141.06m
ARNAArena Pharmaceuticals, Inc. -0.29%89.6313.7%$135.69m
BMRNBioMarin Pharmaceutical, Inc. -1.37%83.704.2%$108.53m
CRSPCRISPR Therapeutics AG -1.12%61.840.6%$107.20m

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.